Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

Paclitaxel 2Carboplatin 2pembrolizumab 1figitumumab 1cabozantinib 1Radiotherapy, Intensity-Modulated 1Hysterectomy 1Cetuximab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Adenosquamous × pembrolizumab × Clear all
NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

University of South Alabama

Phase 2 Terminated
5 enrolled
Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡